Choose a language and wait for the translated text.
The Chinese drugmaker is eligible to receive an upfront payment of $200 million, โwith additional development, regulatory and sales milestones, totalling up to $1.9 โbillion.
AstraZeneca secures ex-China license for Sino Biopharmaceutical's experimental COPD drug | PharmaVoice
